446 related articles for article (PubMed ID: 29392511)
1. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
Bae SC; Lee YH
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC; Song GG
Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Feb; 82(1):64-70. PubMed ID: 33999266
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2018 Jun; 77(5):421-428. PubMed ID: 28324148
[TBL] [Abstract][Full Text] [Related]
8. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
Int J Clin Pharmacol Ther; 2021 Sep; 59(9):618-626. PubMed ID: 34281633
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Song GG; Lee YH
Z Rheumatol; 2020 Feb; 79(1):103-111. PubMed ID: 30725185
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
Ho Lee Y; Gyu Song G
Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Z Rheumatol; 2018 May; 77(4):335-342. PubMed ID: 28097393
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Mar; 82(2):114-122. PubMed ID: 34228181
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of etanercept biosimilars in comparison with etanercept in patients with rheumatoid arthritis who have insufficient response to methotrexate: A network meta-analysis.
Lee YH; Song GG
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):760-767. PubMed ID: 34622769
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis : Meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Z Rheumatol; 2017 Aug; 76(6):528-534. PubMed ID: 27312466
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
Ho Lee Y; Gyu Song G
Z Rheumatol; 2024 Feb; 83(Suppl 1):97-106. PubMed ID: 36607422
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
20. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
